In this study, 371 patients with relapsed or refractory FLT3-ITD or TKD mutation-positive AML were randomized 2:1 to receive 120 mg/day of gilterinitib (247 patients) or salvage chemotherapy (124 patients). Here, FLT3 is linked to acute myeloid leukemia.